Thursday, February 28, 2019
Trident Brands Inc., a biotech and nutraceutical company, Brain Armor® and NorthShore University HealthSystem (NorthShore) have successfully begun laboratory experimentation utilizing Trident Brands’ proprietary formulas for study of their effects on mitigation of the effects of traumatic brain injury. While both severe and mild traumatic brain injury (concussion) have been a major problem for the general population, athletes, and active duty military personnel, no pharmacological treatment has emerged to reduce brain injury or facilitate the brain’s healing process. The cornerstone of the therapy involves the brain’s primary fatty acid, docosahexaenoic acid or DHA, which has previously been shown to have beneficial effects in such injuries, but investigators are also researching the potential for cannabinoids to limit injury or improve upon the healing process. Results are expected to be announced later this year.
"We are enthusiastic about this collaboration and continuing our laboratory's experimental work on brain injury, cellular mechanisms, and protection,” said Julian Bailes, MD, Chairman of the Department of Neurosurgery at NorthShore and co-director of the NorthShore Neurological Institute. “The potential for improvement in the brain's responses to inflammation, compromise in blood flow, traumatic damage, and repetitive impacts are areas of exciting research. This ongoing work should open up areas of additional understanding and insight for better outcomes from mild traumatic brain injury."
“This initial research collaboration with NorthShore will establish a firm foundation for our future research which will focus on determining the potential for prevention of injury and further determining ability to repair after injury. Through this research, Brain Armor will be able to create new, scientifically validated nutritional and supplement programs designed specifically for optimal brain health and improved cognitive performance. We are thrilled to partner with NorthShore in challenging the status quo of current brain-related knowledge,” says Alan Jones, Chief Development Officer for Trident Brands, Inc.
